Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Cited by (1,006)

Items 701–800 of 1,006

1. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
   Aura Muntasell, Mariona Cabo, Sònia Servitja, Ignasi Tusquets, Maria Martinez‐García, Ana Rovira, Federico Rojo, Joan Albanell, Miguel López‐Botet · 2017 · Frontiers in Immunology
2. Immunotherapy in breast cancer: Current status and future directions
   2019 · Advances in Cancer Research
3. Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross‐tolerance
   Vincent Flacher, Christoph H. Tripp, David Gabriel Mairhofer, Ralph M. Steinman, Patrizia Stoitzner, Juliana Idoyaga, Nikolaus Romani · 2014 · EMBO Molecular Medicine
4. Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies
   Amy E. Gilbert, Panagiotis Karagiannis, Tihomir S. Dodev, Alexander Koers, Katie E. Lacy, Debra Hannah Josephs, Pooja Takhar, Jenny L. C. Geh, Ciaran Healy, Mark Harries et al. · 2011 · PLoS ONE
5. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections
   Narges Seyfizadeh, Nayer Seyfizadeh, Justin Hasenkamp, Sara Huerta‐Yépez · 2015 · Critical Reviews in Oncology/Hematology
6. Evolution of anti-HER2 therapies for cancer treatment
   Sagun Parakh, Hui Kong Gan, Adam C. Parslow, Ingrid J.G. Burvenich, Antony Wilks Burgess, Andrew Mark Scott · 2017 · Cancer Treatment Reviews
7. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation
   Josefa Antonia Rodrı́guez · 2017 · Oncology Letters
8. The IL-2/IL-15 Receptor Systems: Targets for Immunotherapy
   Thomas A. Waldmann · 2002 · Journal of Clinical Immunology
9. New approaches to antibody therapy
   Louis M. Weiner, Gregory Paul Adams · 2000 · Oncogene
10. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
    Stefania Bellone, Gianluca Frera, Gianpiero Landolfi, Chiara Romani, Elisabetta Bandiera, Germana Tognon, Juan J. Roman, Alexander Burnett, Sergio L. Pecorelli, Alessandro Davide Santin · 2007 · Gynecologic Oncology
11. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
    Repp, R, van Ojik, H H, Valerius, T, Groenewegen, G, Wieland, G, Oetzel, C, Stockmeyer, B, Becker, W, Eisenhut, M, Steininger, H et al. · 2003 · British Journal of Cancer
12. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
    Rita Nahta · 2012 · ISRN Oncology
13. A Comparison of thein Vitroandin VivoActivities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies
    Camelia Spiridon, Sarah E. Guinn, Ellen S. Vitetta · 2004 · Clinical Cancer Research
14. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment
    Séverine Loisel, Marc C. P. Ohresser, Marc J. Pallardy, David Daydé, Christian Berthou, Guillaume Cartron, Hervé Watier · 2007 · Critical Reviews in Oncology/Hematology
15. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity
    Whitney Shatz-Binder, Shan Chung, Bing Li, Brett Marshall, Max L. Tejada, Wilson Phung, Wendy N. Sandoval, Robert F. Kelley, Justin M. Scheer · 2013 · mAbs
16. Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect
    Joan Albanell, Jose M Baselga · 2001 · JNCI Journal of the National Cancer Institute
17. HER2 as a target for breast cancer therapy
    Elda Tagliabue, Andrea Balsari, Manuela Campiglio, Serenella Maria Pupa · 2010 · Expert Opinion on Biological Therapy
18. CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma
    Christopher T. Rankin, Maria-Concetta Verı́, Sergey N. Gorlatov, Nadine Tuaillon, Steve Burke, Ling Huang, Hector David Inzunza, Hua Li, Shannon Thomas, Syd Johnson et al. · 2006 · Blood
19. Aging, Cancer and Immunity
    Hong Hong, Qi Wang, Jing Li, Hans B. Liu, Xin Meng, Haiyan Zhang · 2019 · Journal of Cancer
20. “Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity
    Lingjun Xiao, Louqian Zhang, Ciliang Guo, Qilei Xin, Xiaosong Gu, Chunping Jiang, Junhua Wu · 2024 · 癌症：英文版
21. Recombinant approaches to IgG-like bispecific antibodies
    Jonathan S. Marvin, Zhenping Zhu · 2005 · Acta Pharmacologica Sinica
22. Anti–Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell Death In vitro and Inhibits Tumor Growth In vivo via a Fc-Independent Mechanism
    Zhennan Gu, Joyce M. Yamashiro, Evelyn A. Kono, Robert Evan Reiter · 2005 · Cancer Research
23. Monoclonal antibody therapies–a ‘constant’ threat to cancer
    Alan N. Houghton, David A. Scheinberg · 2000 · Nature Medicine
24. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells
    Veronika Groh, Yongqing Q. Li, Daniel Cioca, Naomi N. H. Hunder, Wei Wang, Stanley R. Riddell, Cassian Yee, Thomas A. Spies · 2005 · Proceedings of the National Academy of Sciences
25. Principles of tumor immunosurveillance and implications for immunotherapy
    Adrian F. Ochsenbein · 2002 · Cancer Gene Therapy
26. A new therapeutic antibody masks ErbB2 to its partners
    Ali Badache, Nancy E. Hynes · 2004 · Cancer Cell
27. ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective
    Ruchi Saxena, Anila Dwivedi · 2010 · Medicinal Research Reviews
28. Translating basic mechanisms of IgG effector activity into next generation cancer therapies.
    Falk Nimmerjahn, Jeffrey V. Ravetch · 2012 · Europe PMC (PubMed Central)
29. Structure and Function of the Epidermal Growth Factor (EGF⧸ErbB) Family of Receptors
    Daniel J. Leahy · 2004 · Advances in protein chemistry
30. Mechanism of action and resistance to monoclonal antibody therapy
    Neus Villamor, Emili Montserrat, Dolors Colomer · 2003 · Seminars in Oncology
31. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
    Carlos L. Arteaga, Jose M Baselga · 2003 · PubMed
32. Haematological malignancies: at the forefront of immunotherapeutic innovation
    Bachireddy, Pavan, Burkhardt, Ute E., Rajasagi, Mohini, Wu, Catherine J. · 2015 · Nature Reviews Cancer
33. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies
    Thomas R. W. Tipton, Ali Roghanian, Robert J. Oldham, Matthew J. Carter, Kerry L. Cox, Christopher Ian Mockridge, Ruth R. French, Lekh N. Dahal, Patrick J. Duriez, Philip G. Hargreaves et al. · 2015 · Blood
34. The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions
    Juan C. Osorio, Patrick T Smith, David A. Knorr, Jeffrey V. Ravetch · 2023 · Cancer Cell
35. Therapeutic antitumor efficacy of monoclonal antibody against Claudin‐4 for pancreatic and ovarian cancers
    Masayo Suzuki, Mariko Kato‐Nakano, Shinobu Kawamoto, Akiko Furuya, Yuzuru Abe, Hirofumi Misaka, Naoya Kimoto, Kazuyasu Nakamura, So Ohta, Hiroshi Ando · 2009 · Cancer Science
36. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5?-dFUrd in human breast cancer models
    Kaori Fujimoto-Ouchi, Fumiko Sekiguchi, Yutaka Tanaka · 2002 · Cancer Chemotherapy and Pharmacology
37. The Role of Natural Killer Cells in Multiple Sclerosis and Their Therapeutic Implications
    Coralie Chanvillard, Raymond Jacolik, Carmen Infante‐Duarte, Ramesh C. Nayak · 2013 · Frontiers in Immunology
38. Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer
    Mohammad Jahanzeb · 2008 · Clinical Breast Cancer
39. Cardiotoxicity associated with targeted cancer therapies
    ZI CHEN, Di Ai · 2016 · Molecular and Clinical Oncology
40. Monoclonal antibodies: technologies for early discovery and engineering
    Patrick J. Kennedy, Carla Oliveíra, Pedro Lopes Granja, Bruno Filipe Carmelino Cardoso Sarmento · 2017 · Critical Reviews in Biotechnology
41. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
    Tommy A. Brown, Elizabeth Ann Mittendorf, Diane F. Hale, John William Myers, Kaitlin M. Peace, Doreen O. Jackson, Julia M. Greene, Timothy J. Vreeland, Guy Travis Clifton, Alexandros S Ardavanis et al. · 2020 · Breast Cancer Research and Treatment
42. Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer
    Michael H. Kershaw, Jacob T. Jackson, Nicole M. Haynes, Michele W.L. Teng, Maria Moeller, Yoshihiro Hayakawa, Shayna E.A. Street, Rachel Cameron, Jane E. Tanner, Joseph A. Trapani et al. · 2004 · The Journal of Immunology
43. Fc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer
    Jantine E. Bakema, Marjolein van Egmond · 2014 · Current topics in microbiology and immunology
44. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions
    Tom S. Wehrman, William J. Raab, Clayton L. Casipit, Régis Doyonnas, Jason H. Pomerantz, Helen M. Blau · 2006 · Proceedings of the National Academy of Sciences
45. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
    Fariba Mozaffari, Christina Lindemalm, Aniruddha Choudhury, Helena Granstam Björneklett, I Helander, Mats Lekander, Eva Mikaelsson, Bo R Nilsson, M-L Ojutkangas, Anders Österborg et al. · 2007 · British Journal of Cancer
46. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
    F. Barros, Desmond George Powe, Ian Ogilvie Ellis, Andrew R. Green · 2010 · Histopathology
47. T-cell-receptor-like antibodies – generation, function and applications
    Rony Dahan, Yoram Reiter · 2012 · Expert Reviews in Molecular Medicine
48. Stimulatory and inhibitory signals originatingfrom the macrophage Fcγ receptors
    Jeffrey S. Gerber, David M. Mosser · 2001 · Microbes and Infection
49. A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice
    Gregory Paul Adams, Calvin C. Shaller, Ekaterina Dadachova, Heidi H. Simmons, Eva M Horak, Abohawariat Tesfaye, Andres J. Klein–Szanto, James D. Marks, Martin W. Brechbiel, Louis M. Weiner · 2004 · Cancer Research
50. Recombinant Anti-Human HER2/ neu IgG3-(GM-CSF) Fusion Protein Retains Antigen Specificity and Cytokine Function and Demonstrates Antitumor Activity
    Jay S. Dela Cruz, K. Ryan Trinh, Sherie Leaver Morrison, Manuel L. Penichet · 2000 · The Journal of Immunology
51. Cancer vaccines: on the threshold of success
    Leisha A. Emens · 2008 · Expert Opinion on Emerging Drugs
52. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
    Ting Gui, Keng Shen · 2012 · Cancer Epidemiology
53. Effects of Estrogen on Fracture Healing in Mice
    Frank Timo Beil, Florian Barvencik, Matthias Gebauer, Sebastian A Seitz, Johannes Maria Rueger, Anita A. Ignatius, Pia Pogoda, Thorsten Schinke, Michael Amling · 2010 · The Journal of Trauma: Injury, Infection, and Critical Care
54. Myeloid cells as effector cells for monoclonal antibody therapy of cancer
    Rens Braster, Tom G. O’Toole, Marjolein van Egmond · 2013 · Methods
55. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
    Tanya L. Repka, Elena Gabriela Chiorean, Juliette Gay, Katherine E. Herwig, Virginia Kohl, Douglas Yee, Jeffrey S. Miller · 2003 · PubMed
56. Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
    Guillaume Cartron, Ralf Ulrich Trappe, Philippe Solal‐Céligny, Michael J. Hallek · 2011 · Clinical Cancer Research
57. Treatment of HER-2/ neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/ neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction
    Corinna Warburton, Wieslawa H. Dragowska, Karen A. Gelmon, Stephen Chia, Hong Yan, Dana Masin, Tetyana Denyssevych, Anne E. Wallis, Marcel B. Bally · 2004 · Clinical Cancer Research
58. Multiple pathways to tumor immunity and concomitant autoimmunity
    Mary Jo Turk, Jedd D. Wolchok, Jose Alejandro Guevara-Patino, Stacie M. Goldberg, Alan N. Houghton · 2002 · Immunological Reviews
59. Monoclonal antibodies as therapeutics in oncology
    Mohit Trikha, Yan Li, Marian T. Nakada · 2002 · Current Opinion in Biotechnology
60. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
    Javier Rodríguez, Ruth Zárate, Eva Bandrés, Valentina Boni, A Borrego Hernandez, Jesús Javier Sola, Beatriz Honorato, Nerea Bitarte, Jesús García‐Foncillas · 2012 · European Journal of Cancer
61. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
    Frauke Henjes, Christian Bender, Silvia von der Heyde, Lisa Braun, Heiko Mannsperger, C Schmidt, Stefan Wiemann, Max Hasmann, Sebastian Aulmann, Tim Beißbarth et al. · 2012 · Oncogenesis
62. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
    Young Ho Lee, Sang‐Cheol Bae, Gwan Gyu Song · 2010 · Rheumatology International
63. Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase
    Bruce Montgomery, Ekram Makary, Kathy Schiffman, Vivian Goodell A, Mary Lenora Disis · 2005 · Cancer Research
64. Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms
    Patricia Culp, Donghee Choi, Yongke Zhang, Johnny Yin, Pui Seto, Suzanne E. Ybarra, Mian Su, Mien Sho, Roxanne Steinle, Melanie H.L. Wong et al. · 2010 · Clinical Cancer Research
65. Antibodies as therapeutic agents: vive la renaissance!
    LH Stockwin, S Holmes · 2003 · Expert Opinion on Biological Therapy
66. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
    Carlos L. Arteaga, Stacy L. Moulder, F. Michael Yakes · 2002 · Seminars in Oncology
67. Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response
    Birgit Lehmann, Markus Biburger, Christin Brückner, Andrea Ipsen-Escobedo, Sina Gordan, Christian H.K. Lehmann, David Voehringer, Thomas Winkler, Niels Schaft, Diana Dudziak et al. · 2017 · Science Immunology
68. Kinetic analysis of novel mono‐ and multivalent VHH‐fragments and their application for molecular imaging of brain tumours
    Umar Haris Iqbal, Ulrike Trojahn, Homam Albaghdadi, J Zhang, Maureen D. O'Connor‐McCourt, Danica B Stanimirovic, Bogusław Tomanek, Garnette Roy Sutherland, Abedelnasser Abulrob · 2010 · British Journal of Pharmacology
69. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy
    Nikola Holtkamp, Elke Malzer, Jan Zietsch, Ali Fuat Okuducu, Jana Mucha, Christian Mawrin, Victor‐F. Mautner, Hans‐Ulrich Schildhaus, Andreas von Deimling · 2008 · Neuro-Oncology
70. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab
    Jakub Svoboda, Robert M. Kotloff, Donald Edward Tsai · 2006 · Transplant International
71. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells
    Lars Fischer, Olaf Penack, Chiara Gentilini, Axel Nogai, Arne Muessig, Eckhard Thiel, Lutz Uharek · 2006 · Experimental Hematology
72. Monoclonal antibody therapeutics and apoptosis
    Dale L. Ludwig, DANIEL SANTIAGO PEREIRA, Zhenping Zhu, Daniel J. Hicklin, Peter Böhlen · 2003 · Oncogene
73. Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy
    Atul Bedi, Xiaofei Chang, Kimberly Ann Noonan, Vui Pham, Rishi Bedi, Elana Judith Fertig, Michael Considine, Joseph A. Califano, Ivan Borrello, Christine H. Chung et al. · 2012 · Molecular Cancer Therapeutics
74. STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
    Lekh N. Dahal, Lang Dou, Khiyam Hussain, Rena Liu, Alexander Earley, Kerry L. Cox, Salome Murinello, Ian Tracy, Francesco Forconi, Andrew J. Steele et al. · 2017 · Cancer Research
75. Antibodies in oncology
    Vinochani Pillay, Hui Kong Gan, Andrew Mark Scott · 2011 · New Biotechnology
76. Modulating Antibody Functionality in Infectious Disease and Vaccination
    Bronwyn M. Gunn, Galit Alter · 2016 · Trends in Molecular Medicine
77. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours
    Mira M. Shenouda, Amy E. Gillgrass, Tina Nham, Richard T. Hogg, Amanda J. Lee, Marianne V. Chew, Mahsa Shafaei, Craig W Aarts, Dean Anthony Lee, John A. Hassell et al. · 2017 · Breast Cancer Research
78. Treatment of metastatic cervical cancer: Future directions involving targeted agents
    Iván Díaz-Padilla, Bradley J. Monk, Helen J MacKay, Ana Oaknin · 2012 · Critical Reviews in Oncology/Hematology
79. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
    Leisha A. Emens, R. Todd Reilly, Elizabeth M. Jaffee · 2005 · Endocrine Related Cancer
80. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
    Thomas S. Lin, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Jennifer L. Webb, Sharon Waymer, Mollie E. Moran, Margaret S. Lucas, Sherif Shafik Farag, John C. Byrd · 2004 · Blood
81. Dendritic Cells in Cancer Immunotherapy
    Annelie J. E. Vulink, Kristen J. Radford, Cornelis J.M. Melief, Derek N.J. Hart · 2007 · Advances in cancer research
82. Comparative functional characterization of canine IgG subclasses
    Lisa M. Bergeron, Erin E. McCandless, Steve A. Dunham, Bill Dunkle, Yaqi Zhu, John A. Shelly, Sandra Lightle, Andrea J. Gonzales, Graeme Bainbridge · 2013 · Veterinary Immunology and Immunopathology
83. Macrophages and cancer
    Alessandra Nardin · 2008 · Frontiers in bioscience
84. IgA antibodies for cancer therapy
    Michael Dechant, Thomas Valerius · 2001 · Critical Reviews in Oncology/Hematology
85. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Kathleen E. Phillips, Bert Herring, L. Wilson, M S Rickford, Meili Zhang, C K Goldman, J. Yun Tso, Thomas A. Waldmann · 2000 · PubMed
86. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity
    Rintaro Moroi, Katsuya Endo, Yoshitaka Kinouchi, Hisashi Shiga, Yoichi Kakuta, Masatake Kuroha, Yoshitake Kanazawa, Yosuke Shimodaira, Takahiko Horiuchi, Seiichi Takahashi et al. · 2013 · Immunogenetics
87. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies
    Karl R. VanDerMeid, Michael Rusty Elliott, Andrea M Baran, Paul M. Barr, Charles C. Chu, Clive S. Zent · 2018 · Cancer Immunology Research
88. The emerging role of rituximab in organ transplantation
    Yolanda Tai Becker, Milagros Samaniego, Hans W. Sollinger · 2006 · Transplant International
89. Low-affinity Fcγ receptors, autoimmunity and infection
    Lisa C. Willcocks, Kenneth G. C. Smith, Menna Ruth Clatworthy · 2009 · Expert Reviews in Molecular Medicine
90. Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
    Peter S. Kim, Todd D. Armstrong, Song Hong, Matthew E. Wolpoe, Vivian Lee Weiss, Elizabeth A. Manning, Lan Huang, Satoshi Murata, George Sgouros, Leisha A. Emens et al. · 2008 · Journal of Clinical Investigation
91. Monoclonal Antibody-Based Targeted Therapy in Breast Cancer
    Chantal Bernard-Marty, Fabienne Lebrun, Ahmad Hussein Awada, Martine J Piccart · 2006 · Drugs
92. Antibody-Antigen-Adjuvant Conjugates Enable Co-Delivery of Antigen and Adjuvant to Dendritic Cells in Cis but Only Have Partial Targeting Specificity
    Martin Kreutz, B. Giquel, Qin Hu, Ram Abuknesha, Satoshi Uematsu, Shizuo Akira, Frank Oliver Nestle, Sandra S. Diebold · 2012 · PLoS ONE
93. Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16
    Heiko Singer, Christian Kellner, Harald Lanig, Michael Aigner, Bernhard Stockmeyer, Fuat S. Oduncu, Michael Schwemmlein, Christoph Stein, Kristin Mentz, Andréas Mackensen et al. · 2010 · Journal of Immunotherapy
94. Immunotherapy for melanoma
    Ian K. Komenaka, H. Hoerig, Howard L. Kaufman · 2004 · Clinics in Dermatology
95. Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
    Andrea Li‐Ann Wong, Soo Chin Lee · 2012 · International Journal of Breast Cancer
96. Advances in bispecific biotherapeutics for the treatment of cancer
    Chad May, Puja Sapra, Hans‐Peter Gerber · 2012 · Biochemical Pharmacology
97. Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance
    Alice P. Chung, Xiaojiang Cui, William Audeh, Armando E. Giuliano · 2013 · Clinical Breast Cancer
98. Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer
    Adam Brufsky · 2010 · American Journal of Clinical Oncology
99. Cell Surface Tetraspanin CD9 Mediates Chemoresistance in Small Cell Lung Cancer
    Satoshi Kohmo, Takashi Kijima, Yasushi Otani, Masahide Mori, Toshiyuki Minami, Ryo Takahashi, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Sho Goya et al. · 2010 · Cancer Research
100. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model
     正幸 岩崎, Takeshi Kuwata, Yukari Yamazaki, Nancy A. Jenkins, Neal G. Copeland, Motomi Osato, Yoshiaki Ito, EVERT J. KROON, Guy Sauvageau, Takuro Nakamura · 2004 · Blood